<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-2PMCBO9W</identifier><date>2019</date><creator>Zidar, Nace</creator><relation>documents/doc/2/URN_NBN_SI_doc-2PMCBO9W_001.pdf</relation><relation>documents/doc/2/URN_NBN_SI_doc-2PMCBO9W_001.txt</relation><format format_type="issue">1</format><format format_type="volume">70</format><format format_type="type">article</format><format format_type="extent">str. 19-26</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">4721521</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-2PMCBO9W</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">metformin</subject><subject language_type_id="slv">peroralni antidiabetik</subject><subject language_type_id="slv">Sladkorna bolezen tip 2</subject><subject language_type_id="slv">sulfonilsečnina</subject><subject language_type_id="slv">zaviralec</subject><title>Oral antidiabetic drugs - current overview and future perspectives</title><title>Peroralni antidiabetiki - pregled stanja in pogled v prihodnost</title></Record>